For payers

How much of your medical cost
was avoidable.

Move the three factors using your own book. The first two come from AMIS; the third is the hypothesis, and it is exactly what we propose measuring on your claims before any contract exists.

This is modelled avoidable cost, not promised savings. The number that counts is the one that comes from running a year of your claims against your own baseline.

The model

Move the three factors. What comes out is your avoidable cost.

The arithmetic has three steps and none of them are ours: what you pay out, the share that goes to hospitalisation, and the share of that hospitalisation which starts with a diagnosis that arrived late.

$1.5MM MXN

The Mexican market aggregate was $122,278M in 2024 (AMIS).

65.2%

65.2% is the Mexican market average (AMIS, 2024).

8%

This is the hypothesis. JAMA (2024) found a missed or delayed diagnosis in 23% of patients who escalated to intensive care or died; the default below is deliberately conservative against that figure.

Estimated avoidable cost per year
$78M
MXN · on your own book
$1.5MM × 65.2% hospitalisation × 8% avoidable = $78M
We analyse a year of your claims

This is a hypothesis, not a promise. The effect on admissions is not yet measured in our data: the only number that counts is yours, and it comes from running a year of your claims against your own baseline. That analysis costs nothing and commits you to nothing.

The real number comes from your book, not from this screen.

Give us a year of your claims under an NDA and in three weeks we’ll tell you how much of that spend was avoidable: duplicate testing, repeat visits for the same reason and episodes that escalated after a prior visit. No cost and no commitment.

We analyse a year of your claimsSee the full proposition
Sources

Where every number on this page comes from.

  1. 01
    AMIS, 2024

    $122,278 million pesos paid out by Mexican insurers in medical claims during 2024, up 106% in five years. 65.2% of that payout is hospitalisation.

  2. 02
    JAMA, 2024

    23% of patients who escalated to intensive care or died had a missed or delayed diagnosis.

  3. 03
    WTW · Global Medical Trends, 2026

    Payers’ medical cost rises 10.3% globally in 2026, the third consecutive double-digit year. Latin America accelerates from 10.5% to 11.9%.

  4. 04
    OECD

    Roughly one in five dollars of health spending goes to avoidable or low-value care. The definition of avoidable hospitalisation we use is ambulatory care sensitive conditions (ACSC).

  5. 05
    Infermedica

    27% reduction in in-person visits and an estimated $7–8 saving per interaction in Latin America, with digital triage. Cited as market reference, not as our own result.

  6. 06
    Our own measurement

    96.1% sustained diagnostic accuracy against 55% at the sixth hour of a shift, across 2 million consultations in a country’s public health system, compared against that system’s historical baseline.

What is not yet measured: DeepClinic’s effect on the hospitalisation rate. It does not exist in our data and we do not claim it. It is precisely what we propose measuring on your book, with the methodology agreed before we start.